What is HC Wainwright’s Estimate for Aemetis Q3 Earnings?

Aemetis, Inc (NASDAQ:AMTX) – Equities researchers at HC Wainwright boosted their Q3 2026 EPS estimates for shares of Aemetis in a research note issued to investors on Tuesday, August 18th. HC Wainwright analyst A. Dayal now forecasts that the specialty chemicals company will post earnings of ($0.19) per share for the quarter, up from their prior forecast of ($0.33). The consensus estimate for Aemetis’ current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for Aemetis’ Q4 2026 earnings at ($0.24) EPS, FY2026 earnings at ($0.88) EPS, FY2027 earnings at ($0.41) EPS, FY2028 earnings at $0.38 EPS, FY2029 earnings at $1.84 EPS and FY2030 earnings at $3.10 EPS.

A number of other analysts have also commented on AMTX. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aemetis in a research report on Friday, July 17th. Wall Street Zen lowered Aemetis from a “hold” rating to a “sell” rating in a research report on Saturday, June 6th. Finally, Ascendiant Capital Markets lifted their price target on shares of Aemetis from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, May 22nd. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $11.88.

Aemetis Stock Performance

Shares of NASDAQ AMTX opened at $1.86 on Thursday. The firm’s 50-day moving average price is $1.70 and its 200-day moving average price is $2.07. Aemetis has a 1-year low of $1.30 and a 1-year high of $3.80. The firm has a market capitalization of $134.24 million, a P/E ratio of -2.04 and a beta of 1.48.

Aemetis (NASDAQ:AMTX) last posted its quarterly earnings results on Thursday, August 6th. The specialty chemicals company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.16. The company had revenue of $62.70 million during the quarter, compared to analyst estimates of $67.69 million.

Hedge Funds Weigh In On Aemetis

A number of hedge funds have recently bought and sold shares of the company. Goldman Sachs Group Inc. boosted its stake in shares of Aemetis by 71.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 218,404 shares of the specialty chemicals company’s stock worth $380,000 after buying an additional 91,367 shares during the last quarter. Creative Planning bought a new stake in Aemetis during the second quarter worth $30,000. Russell Investments Group Ltd. lifted its holdings in Aemetis by 412.9% during the second quarter. Russell Investments Group Ltd. now owns 80,754 shares of the specialty chemicals company’s stock worth $200,000 after acquiring an additional 65,010 shares during the period. Jump Financial LLC purchased a new position in Aemetis in the second quarter worth $64,000. Finally, Qube Research & Technologies Ltd bought a new position in Aemetis in the 2nd quarter valued at $246,000. 27.02% of the stock is owned by hedge funds and other institutional investors.

Aemetis Company Profile

Aemetis, Inc, headquartered in Cupertino, California, is a renewable fuels and renewable natural gas producer dedicated to decarbonizing the transportation sector. The company operates two primary business segments: Aemetis Advanced Fuels, which manufactures ethanol, biodiesel and sustainable aviation fuel using patented carbon capture and separation technology; and Aemetis RNG, which develops dairy-based renewable natural gas projects in California for pipeline injection and transportation use.

Since its incorporation in 2006, Aemetis has expanded its production footprint through organic growth and strategic acquisitions.